• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzonitriles

Introduction to 4-(4-Cyanobenzyl)-1,2,4-triazole (CAS No. 112809-27-5)

4-(4-Cyanobenzyl)-1,2,4-triazole, identified by the chemical abstracts service number 112809-27-5, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology. This heterocyclic compound belongs to the triazole class, a structural motif known for its broad spectrum of biological activities. The presence of a 4-cyanobenzyl substituent introduces unique electronic and steric properties, making it a versatile scaffold for drug discovery and molecular design.

The compound's structure consists of a central 1,2,4-triazole ring, which is a fused system of three nitrogen atoms, interconnected with two carbon atoms. This triazole core is highly pharmacophoric, capable of interacting with biological targets through hydrogen bonding and π-stacking interactions. The 4-cyanobenzyl group, attached at the 4-position of the triazole ring, enhances the molecule's lipophilicity and potential for membrane permeability, which are critical factors in drug bioavailability.

In recent years, there has been a surge in research focused on developing novel triazole derivatives as potential therapeutic agents. The 1,2,4-triazole scaffold has been extensively studied for its antimicrobial, anti-inflammatory, and anticancer properties. Specifically, derivatives of this class have shown promise in inhibiting enzymes such as kinases and phosphodiesterases, which are implicated in various diseases. The 4-(4-cyanobenzyl)-1,2,4-triazole structure represents an evolution of these derivatives, incorporating the 4-cyanobenzyl moiety to modulate reactivity and binding affinity.

One of the most compelling aspects of 4-(4-cyanobenzyl)-1,2,4-triazole is its potential application in the development of targeted therapies. The cyanobenzyl group can serve as a handle for further functionalization via cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings. These reactions allow for the introduction of diverse substituents at specific positions on the benzyl ring or elsewhere on the molecule. Such modularity enables medicinal chemists to fine-tune pharmacokinetic and pharmacodynamic properties to optimize drug-like characteristics.

Recent studies have highlighted the role of triazole-containing compounds in modulating immune responses. For instance, certain triazole derivatives have been reported to exhibit immunomodulatory effects by interacting with cytokine receptors or intracellular signaling pathways. The cyano group in the 4-(4-cyanobenzyl)-1,2,4-triazole moiety may contribute to this activity by serving as a proton acceptor or participating in hydrogen bonding interactions within biological targets. This feature makes the compound an attractive candidate for investigating novel immunotherapeutic strategies.

The synthesis of 4-(4-cyanobenzyl)-1,2,4-triazole involves multi-step organic transformations that require precise control over reaction conditions. A common synthetic route begins with the condensation of guanidine with an appropriate α-halo ketone or aldehyde to form the triazole core. Subsequent functionalization at the 4-position is achieved through nucleophilic substitution or metal-catalyzed coupling reactions. Advances in synthetic methodologies have enabled higher yields and purities of this compound, facilitating its use in downstream applications.

In vitro studies have demonstrated that 4-(4-cyanobenzyl)-1,2,4-triazole exhibits promising biological activity against several disease-related targets. For example, preliminary data suggest that this compound may inhibit certain tyrosine kinases involved in cancer progression by competing with ATP for binding sites on these enzymes. Additionally, its interaction with DNA repair enzymes has been explored as a potential mechanism for inducing apoptosis in tumor cells. These findings underscore its therapeutic potential and justify further investigation into its mechanism of action.

The pharmaceutical industry has increasingly recognized the value of heterocyclic compounds like triazoles in drug development. The structural diversity offered by these molecules allows for extensive chemical space exploration without compromising core pharmacophoric features. The incorporation of functional groups such as cyano or benzyl moieties enhances molecular complexity while maintaining bioactivity. This balance between structure and function makes compounds like 4-(4-cyanobenzyl)-1,2,4-triazole valuable tools for medicinal chemists seeking novel therapeutic agents.

As research continues to uncover new applications for triazole derivatives, it is likely that compounds like CAS No. 112809-27-5 will play an increasingly important role in addressing unmet medical needs. Collaborative efforts between academic researchers and industry scientists are essential to translating laboratory discoveries into clinical candidates. By leveraging cutting-edge synthetic techniques and computational modeling tools, 1 , 2 , 3 , 5 , 6 ,7, this compound could emerge as a lead molecule for future drug development programs.

• 1286189-21-6(btx)
• 112809-52-6(Iso Letrozole)
• 16227-13-7(4-benzyl-4H-1,2,4-triazole)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)